Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.
The US-based company behind glucose-monitoring systems could become a giant on the diabetes device market following a rumored acquisition of Insulet, a maker of insulin pumps.
CEO Paul Chaplin reports that Bavarian is making more doses of its vaccine against monkeypox due to the recent outbreak.
Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.
Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.
Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.
Almirall is launching psoriasis cream Wynzora in Denmark. The treatment has been inlicensed from Danish firm MC2 Therapeutics, where the CEO says ”it is a special feeling” to see Wynzora launched in its home country.
Over the course of three days, Bavarian Nordic has seen its share price increase by around DKK 100 (USD 14.3).
As the firm concludes operational activities following a sale of the business to Kempharm, Oprhazyme has halved its board of directors. The firm’s chair will also step down following its AGM in June.
The discovery of monkeypox in several countries has led to share price increases at a number of companies with smallpox vaccines or treatments in their portfolios, including Bavarian Nordic.
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Miss anything?
Britt Meelby Jensen, who was appointed the new chief executive of Ambu yesterday, is the obvious candidate to rebuild trust in the medtech firm after years of downgrades, say analysts.
Carsten Hellmann, the chief executive of allergy firm ALK-Abelló, has sold company shares for almost DKK 11m (USD 1.5m).
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior Chemical Safety Advisor 
Scientific Writer 
Senior QA Specialist 
Senior IT Network Engineer 
Production Director 
Cell Culture Scientist/Senior Scientist 
Innovation Project Manager, Display Unit 
IRT Manager, Clinical Drug Supply Analytical Senior Scientist 
Account Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore Director of Toxicology 
Director Global Engineering Biostatistician SAP System Specialist (Product Supply) – Business Application Services 
Senior Project Manager (GMP - Life Science) Industrial Designer- Design Engineer 
Key Account Manager, Europe and Asia 
Nordic Medical Affairs Manager Consultant Manager 
Project Manager & Scrum Master 2 Sales Representatives and Product Specialists Biomarker Operations Lead Chemist for Incoming Materials in QC Department 
